Cooper Companies Rises After Topping Q4 Estimates, Issues Strong 2026 Outlook
Shares of the medical device maker gained after its eighth consecutive earnings beat, driven by robust sales in its contact lens and women's health divisions.
Shares of The Cooper Companies (NASDAQ:COO) advanced in trading after the global medical device firm reported fiscal fourth-quarter earnings and revenue that surpassed analyst expectations and provided an upbeat financial forecast for fiscal year 2026.
The stock closed up 1.38% at $77.03 after the company posted its eighth consecutive quarterly earnings beat. Cooper reported fourth-quarter non-GAAP earnings per share of $1.15, exceeding consensus estimates by $0.08. Quarterly revenue came in at $1.07 billion, slightly ahead of the $1.06 billion Wall Street had anticipated.
The positive results were fueled by steady growth across the company’s two core business segments, CooperVision and CooperSurgical. "We had a solid fourth quarter to close out a record year for CooperCompanies," said Al White, President and CEO of The Cooper Companies, in a statement accompanying the results. "Both CooperVision and CooperSurgical performed well, and our success is flowing through to the bottom line with record annual profitability."
CooperVision, the company's largest division specializing in contact lenses, posted revenues of $700.8 million, an increase of 6% from the same period last year. This growth was largely driven by strong demand for its MyDay and MiSight product lines. MiSight, a lens designed to slow the progression of myopia in children, saw a remarkable 37% sales increase, signaling strong traction in a key growth market.
Meanwhile, the CooperSurgical division, which focuses on medical devices and fertility solutions for women's health, reported revenue of $364.4 million, a modest 2% year-over-year increase. The company noted that it expects its fertility business to be a significant growth driver in the coming year.
Investors responded positively to the company's forward-looking guidance, which projects continued momentum. For fiscal year 2026, The Cooper Companies anticipates non-GAAP EPS to be in the range of $4.45 to $4.60, with revenues forecasted between $4.3 billion and $4.34 billion. This outlook was described by the company as being "above expectations," suggesting confidence in sustained operational strength and market demand.
The San Ramon, California-based company, with a market capitalization of approximately $15.16 billion, has demonstrated consistent performance in a competitive healthcare landscape. Analysts currently hold a "Moderate Buy" consensus rating on the stock, with an average price target of around $83.00, implying further potential upside from its current trading level.
Looking ahead, Cooper's strategy appears focused on capitalizing on its innovative product portfolio and expanding its market reach. The strong performance of specialized products like MiSight highlights the success of its investment in higher-growth niches within the vision care market. As detailed in its fourth-quarter financial announcement, the company's ability to consistently execute and deliver growth across its diversified healthcare segments will remain a key focus for investors throughout fiscal 2026.